Dagnew, A. F. Et Al. 2019. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. The Lancet Infectious Diseases , vol.19, no.9 , 988-1000.

Dagnew, A. F., İLHAN, ., Lee, W., Woszczyk, D., Kwak, J., Bowcock, S., ... Sohn, S. K.(2019). Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. The Lancet Infectious Diseases , vol.19, no.9, 988-1000.

Dagnew, Alemnew Et Al. "Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis," The Lancet Infectious Diseases , vol.19, no.9, 988-1000, 2019

Dagnew, Alemnew F. Et Al. "Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis." The Lancet Infectious Diseases , vol.19, no.9, pp.988-1000, 2019

Dagnew, A. F. Et Al. (2019) . "Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis." The Lancet Infectious Diseases , vol.19, no.9, pp.988-1000.

@article{article, author={Alemnew F Dagnew Et Al. }, title={Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis}, journal={The Lancet Infectious Diseases}, year=2019, pages={988-1000} }